Cite
HARVARD Citation
Ko, A. et al. (n.d.). LBA29CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. Annals of oncology. p. . [Online].